News
Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...
Hydroxychloroquine is tied to reduced preeclampsia risk but not preterm birth risk in pregnant patients with lupus in a ...
StockStory.org on MSN1d
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...
A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...
3don MSN
Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results